Abstract
BACKGROUND- Until recently, therapy for multiple sclerosis was limited to management of symptoms and treatment of acute relapses. Increasingly, effective therapies that alter the disease course are becoming available. REVIEW SUMMARY- The purpose of this article is to review emerging drug therapies for multiple sclerosis and to discuss issues that remain controversial. Tizanidine and 4-aminopyridine are two new options for symptomatic management. The role of corticosteroids in the treatment of acute relapses and as chronic therapy is discussed. A comparison is presented of interferon β-1b (Betaseron), interferon β-1a (Avonex), and copolymer-1 (Copaxone), the three options with proven efficacy for relapsing-remitting disease. Finally, a number of other treatment options are in late stages of testing. CONCLUSION- Rapidly, an increasing number of treatment options for multiple sclerosis are emerging.
| Original language | English |
|---|---|
| Pages (from-to) | 342-355 |
| Number of pages | 14 |
| Journal | Neurologist |
| Volume | 2 |
| Issue number | 6 |
| State | Published - Nov 1996 |
Keywords
- Copolymer-1
- Corticosteroids
- Immunosuppression
- Interferon β-1
- Oral tolerance
- Potassium channel blockers
- Spasticity
- Symptomatic treatment
Fingerprint
Dive into the research topics of 'Emerging therapies for multiple sclerosis'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver